Skip to content
Search
Please enter at least 3 characters.

Latest Stories

NPA Insurance enhances locum pharmacist professional indemnity policy

Locum pharmacists' indemnity insurance npa
Healthcare professionals working in a medication store. locum pharmacists

Under the updated policy, locum pharmacists will no longer pay charges for vaccine administration

NPA Insurance, a wholly owned subsidiary of the National Pharmacy Association (NPA), has updated its professional indemnity policy for locum pharmacists to better support their expanding roles in healthcare.

The enhanced policy now includes private and NHS prescribing cover for weight loss and other areas of competence, which is available for locums working in pharmacy, general practice and hospital settings.


Policyholders will benefit from an extended range of cover, which includes, as standard, the delivery of the NHS Pharmacy First service, the expanded pharmacy contraception service, and the re-launched hypertension case-finding service.

Moreover, NPA Insurance has removed charges for vaccine administration, including COVID-19, flu, and travel.

Locum pharmacists will also have access to NPA Insurance’s award-winning claims team as part of the new policy.

For those involved in specialised treatments, locum pharmacists can purchase additional cover for both NHS and private independent prescribing. This includes cover for procedures like Botox administration, non-permanent dermal fillers, and cryotherapy.

The insurance company also offers bespoke policies tailored to specialist needs, and designated prescribing practitioner cover, enabling training of newly qualified independent prescribers.

Lisa Banks, MD of NPA Pharmacy Insurance, commented on the policy enhancement: “Our unrivalled knowledge and legal perspective to protection provides our policyholders with a genuinely holistic approach to risk and claims management.”

She pointed out that, unlike other pharmacy indemnity providers, NPA Insurance acts as the underwriter and makes “decisions on cover which are not restrained by bureaucratic processes, or changes in risk appetite.”

“We can flex our agility to provide bespoke insurance solutions for each individual case, and our qualified lawyers have the autonomy to make quick and informed decisions,” she added.

In addition to the enhanced indemnity cover, locum policyholders can access a range of NPA’s online resources at a discounted price.

There’s more: policyholders can become an NPA Associated Pharmacist and gain access to training, an advice and support line for clinical queries, drug tariff and medicine safety guidance, and SOPs.

More For You

Mike Hewitson, superintendent pharmacist & managing director of Beaminster Pharmacy

Mike Hewitson elected as NPA board member for England

Mike Hewitson elected as NPA board member for England: New term begins April

Mike Hewitson, superintendent pharmacist & managing director ofBeaminster Pharmacy, has been elected as the next National Pharmacy Association (NPA) board member for England.

Since 2023, Hewitson has served as chair of Community Pharmacy Dorset. He is also a member of Somerset Council and a Non-Executive Director at HubRx.

Keep ReadingShow less
Store closures 2024: Chemists among hardest hit

Over 600 chemist shops belonging to multiples and chains were closed last year

Getty Images

35 shops closed per day last year, chemists worst affected

More shops are expected to exit the UK high streets driven by driven by rising operational costs and a continued shift towards online shopping and transactions.

According to figures from PwC, a total of 12,804 outlets operated by chains (those with five or more locations) exited high streets, shopping centres and retail parks in 2024 – equivalent to 35 closures per day.

Keep ReadingShow less
Empty pharmacy shelves due to UK medicine shortages.

The government has said it's investing up to £520m to manufacture more medicines

Pic credit: iStock

Brexit blamed for UK medicine shortages with "little sign of recovery"

The UK is facing “a worsening situation” with drugs shortages compared to the rest of Europe as a result of Brexit, according to the Nuffield Trust health thinktank.

It comes of the back of data that revealed that the department of health and social care (DHSC) received 1,938 notifications of disruptions to medicine supply last year – the highest in four years.

Keep ReadingShow less
Alert! Patients on Promixin should be switched to alternatives by 30 April

Promixin is licensed for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in adults and children with cystic fibrosis

Getty Images

Medicine shortage: Promixin to be discontinued from May 2025

The Department of Health and Social Care (DHSC) and NHS England have issued a national patient safety alert regarding the upcoming shortage of Promixin (colistimethate).

The alert, issued on 17 March 2025, states that Promixin (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) will be discontinued from early May 2025, with stocks expected to be exhausted by this time.

Keep ReadingShow less
PAGB welcomes new vice-presidents and treasurer to Board

Rob Elliott and Bas Vorsteveld ( L-R)

Bas Vorsteveld will now oversee the Kenvue’s business in Northern Europe

PAGB appoints new vice-presidents and treasurer to Board

PAGB, the consumer healthcare association, has announced the appointment of two new vice-presidents and a treasurer to their Board.

Bas Vorsteveld, area managing director for Northern Europe at Kenvue, and Rob Elliott, OTC centre of excellence lead at Viatris, have been elected as vice-presidents.

Keep ReadingShow less